Compare PMN & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMN | MCN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.5M | 127.0M |
| IPO Year | 2022 | 2004 |
| Metric | PMN | MCN |
|---|---|---|
| Price | $10.53 | $5.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 89.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $5.46 |
| 52 Week High | $27.40 | $6.39 |
| Indicator | PMN | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 22.84 |
| Support Level | $10.55 | N/A |
| Resistance Level | $11.37 | $6.02 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 74.37 | 5.89 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.